1 414-918-9890

Industry Committee

    Ke Liu, MD, PhD (Chair)

Ke Liu, MD, PhD, is Chief Development Officer of Marengo Therapeutics.  Ke has over 20 years of experience in the field of oncology, immuno-oncology, and cell and gene therapy, most recently serving as Senior Vice President and led the key regulatory activities at Sana Biotechnology. Prior to Sana, he spent more than 17 years working at the U.S. Food and Drug Administration (FDA) where he held leadership roles at the Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), and the Oncology Center of Excellence (OCE). Ke has made major contributions to the field of Oncology and led the clinical evaluations and approvals of key first-in-class cancer therapeutics over the past decade, including checkpoint inhibitors, chimeric antigen receptor (CAR) T cells, T cell receptor (TCR) modified T cells, genome-edited products, neoantigen-based therapies, adoptive T cell therapies, oncolytic viral therapy, dendritic cell therapy, and combinations of these immune-oncologic therapeutics with checkpoint inhibitors and other agents.

Ke received his M.D. from Henan Medical University in China and his Ph.D. in molecular biology from Cornell University. He completed his internal medicine internship and residency at Albert Einstein College of Medicine, his medical oncology fellowship at the National Cancer Institute (NCI), and additional cancer immunotherapy training at the NCI’s Surgery Branch. Ke is an internist and medical oncologist certified by the American Board of Internal Medicine.

  Jianda Yuan, MD, PhD (Co-Chair)

Dr. Jianda Yuan is the Senior Medical Director of Translational Oncology at Early Oncology Development Department of Merck Research Laboratory. He oversees several Merck sponsored Keytruda clinical trials and external academic collaborative clinical studies. He collaborates internally and externally scientific experts to develop a robust portfolio of research to answer critical questions about mechanisms of cancer immunotherapy response and resistance. Before he joined Merck in February, 2016, He established and led the translational biomarker research at Ludwig Center for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center from 2002 to 2016. His research interest is translational medicine and biomarker discovery for immune checkpoint blockade immunotherapy with approximately 70 peer-reviewed articles, including publication in Science, NEJM, Nature Medicine, Nature Immunology, PNAS, Blood, Journal of Immunology, Clinical Cancer Research and Journal Immunotherapy of Cancer. He is a member of SITC, COHAN, AACR and ASCO. Dr. Yuan is an Associate Editor of the Journal Immunotherapy of Cancer. He served as a Member of the steering committee for the CRI-CIC from 2006 to 2011. He is Group Chair of the SITC Biomarker Task Force and the Chair of the SITC Tumor Mutational Burden subcommittee.

  Yufeng Li, PhD

Yufeng Li, PhD, is currently Executive Director of Clinical Development at Qilu Pharma, based in Philadelphia, PA.

Yufeng graduated from Shanghai Jiao Tong University, and obtained PhD training at UT MD Anderson Cancer Center at Houston, focusing on cancer immunology and immunotherapy. Subsequently, he spent many years at GSK to discover and develop medicines for cancer patients. Prior to Qilu, Yufeng has also served China biotech
companies (Ascentage and Transcenta) to oversee their US and global clinical programs.

Yufeng is active for community based volunteer activities, including serving important roles in organizations such as Sino-American Pharmaceutical Professionals Association (SAPA), the Main Line Chinese Culture Center (MLCCC) etc.



  Weili Sun, MD, PhD

Dr. Sun is the Senior Medical Director of Clinical Research at Janssen Pharmaceutical, and Adjunct Associated Professor at University of Southern California. She oversees Janssen sponsored late phase clinical trials in multiple myeloma. Before she joined Janssen, she was an associate professor and clinical investigator at City of Hope Medical Center and served as study chairs for several national and international clinical studies in pediatric leukemia.

Weili received her M.D. from Sun Yat-Sen University of Medical Sciences and Ph.D from St. Jude Children’s Research Hospital. She completed her pediatric residency at Albert Einstein College of Medicine, pediatric hematology oncology fellowship at Memorial Sloan Kettering Cancer Center. Weili is a board certified pediatrician and pediatric hematology/oncologist.


  Yaping Shou, MD, PhD

Yaping Shou, MD, PhD, is currently a venture partner with Lilly Asia Ventures. Prior to joining LAV, Dr. Shou was the chief medical officer of Trillium Therapeutics and prior to that, the executive medical director with Takeda Pharmaceuticals. Dr. Shou has over 20 years of global clinical development experience in both big pharma (GlaxoSmithKline, Novartis, and Takeda) and small biotech (Trillium) companies. She has made critical contributions to the development and approval of multiple oncology drugs (lapatinib, pazopanib, nilotinib, sonidegib, and ixazomib). She also led significant clinical progress at Trillium in recent years that led to Pfizer’s $2.3b acquisition of Trillium.  Dr. Shou has a unique blend of expertise across clinical development and translational research, and advocates integration of science and innovative trial design into rational clinical development. In her current role, Dr. Shou leverages her development expertise to support investment decisions. She also provides strategic guidance to help businesses achieve financial growth and optimal organizational performance.

Dr. Shou received her MD degree at Zhejiang University, her PhD in Cellular and Molecular Biology from Drexel University, and her postdoctoral fellowship training at National Cancer Institute. As a female executive, Dr. Shou graduated from a 12-month woman leadership program for high-potential women led by WOMAN Unlimited, Inc.


Huichun Zhan, MD, MS

Photo and Bio Coming Soon

Cookie Notice

This website uses cookies to deliver to you the best experience possible on the CAHON website. By continuing to use this site, you are providing to us your consent to ensure you receive such an experience. View our privacy policy to learn more.